Ovarian Cancer September Journal Scan

Panel

member photo
Brian Slomovitz, MD

Professor of Obstetrics & Gynecology
Florida International University
Gynecologic Oncologist
Broward Health

member photo
Thomas Herzog, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

member photo
Dana Chase, MD, FACOG

Associate Professor
Creighton University
University of Arizona College of Medicine
Gynecologic Oncologist, Arizona Oncology

In this month's journal scan, our panel reviews:

  1. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
  2. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
  3. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect

Ovarian Cancer August Journal Scan

Panel

member photo
Dana Chase, MD, FACOG

Associate Professor
Creighton University
University of Arizona College of Medicine
Gynecologic Oncologist, Arizona Oncology

member photo
Thomas Herzog, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

member photo
Brian Slomovitz, MD

Professor of Obstetrics & Gynecology
Florida International University
Gynecologic Oncologist
Broward Health

In this ovarian cancer journal scan, our panel reviews:

1) BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

2) Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

3) Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).


Ovarian Cancer July Journal Scan

Panel

member photo
Thomas Herzog, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

member photo
BJ Rimel, MD

Assistant Professor
Obstetrics and Gynecology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

member photo
Brian Slomovitz, MD

Professor of Obstetrics & Gynecology
Florida International University
Gynecologic Oncologist
Broward Health

In this ovarian cancer journal scan, our panel reviews:

1) The Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab

2) The Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer

3) The randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer


Ovarian Cancer Journal Scan

Panel

member photo
BJ Rimel, MD

Assistant Professor
Obstetrics and Gynecology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

member photo
Brian Slomovitz, MD

Professor of Obstetrics & Gynecology
Florida International University
Gynecologic Oncologist
Broward Health

member photo
Thomas Herzog, MD

Professor of Obstetrics and Gynecology
Deputy Director
University of Cincinnati Cancer Institute

In this ovarian cancer journal scan, our panel reviews:

1) The results of the randomised phase III GOG-0213 study that involved patients with platinum-sensitive, recurrent epithelial ovarian cancer, secondary surgical cytoreduction followed by chemotherapy.

2) The Food and Drug Administration approval of niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.

3) The randomized Phase II Trial of Nivolumab vs. Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.